$NEO

Aunan Greg D sold $321K of NEO

Aunan Greg D (Chief Accounting Officer) sold 20,000 shares of NEOGENOMICS INC (NEO) at $16.07 ($0.32M total) on 2026-08-04.

Original reporting
SEC EDGAR · Aunan Greg D
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NEO
Neutral
low confidence
Mentioned
$NEO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEONeutralLow
01

Why it matters

A single officer open-market sale can modestly affect sentiment, but it is not a fundamental datapoint like earnings, guidance, or a deal.

02

Market read

Traders may note the insider sale for sentiment, but there is no additional company-specific catalyst in the text.

03

What to watch

The filing does not include motives, and the post-sale holdings (5,153 shares) suggest the sale may be part of routine personal liquidity rather than a large conviction shift.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 for a sale dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for NEOGENOMICS.

Company-level read

Ticker impact

$NEONeutralLow confidence
Context

NEOGENOMICS insider Aunan Greg D sold 20,000 shares at $16.07 on 2026-08-04, per a newly filed Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 provides transaction details but no accompanying company-specific catalyst, guidance change, or regulatory/legal event.

Market effects

No clear sector read-through from a single insider sale.

None.

None.

Counterpoint

Insider sales are often planned for diversification or tax needs; the absence of a stated 10b5-1 plan does not automatically imply negative information.

Key entities

  • NEOGENOMICS INC

    Subject of the Form 4 insider transaction disclosure.

  • Aunan Greg D

    Chief Accounting Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

Med

Medicare Expands Coverage for NeoGenomics RaDaR ST Assay for Immunotherapy

NeoGenomics' RaDaR ST assay received expanded Medicare coverage for immunotherapy monitoring in late-stage solid tumors, adding to its existing indications. The assay helps track treatment response and distinguish true progress from inflammation. According to the company, it detects circulating tumor DNA at low levels, supporting recurrence risk assessment and treatment monitoring.

$NEOMedAI 8/10

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeoGenomics (NEO) stock rose 22.3% in the past month, hitting a 52-week high of $17.08. The company beat earnings estimates in the last four quarters. For the current fiscal year, it expects $0.18 EPS on $802.67M revenue, with a 50% EPS growth. NEO has a Zacks Rank of #2 (Buy) and a VGM Score of B. Halozyme Therapeutics (HALO) is also highlighted as a strong performer in the industry.

$NEOHighAI 9/10

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics (NASDAQ: NEO) reported Q2 adjusted gross margin of 48.1% and adjusted EBITDA of $14.4 million. It raised 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA to $56 million to $58 million. Management discussed RaDaR ST and PanTracer LBx reimbursement progress, NovaSeq X transitions, and a $316 million convertible note raise. Cash was $145.5 million.

$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

$NEOMedAI 9/10

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics (NEO) shares rose 15.8% after the company reported Q2 2026 adjusted EPS of $0.05 on revenue of $201.7 million, beating Wall Street forecasts of $0.03 and $197.3 million. NeoGenomics also raised full-year guidance to about $804 million revenue and $0.19 adjusted EPS.